Table of Content


Table of Contents
Introduction
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Therapeutics Development
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Therapeutics Assessment
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Companies Involved in Therapeutics Development
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Drug Profiles
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1)
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AbbVie Inc, H1 2019
Pipeline by AC Immune SA, H1 2019
Pipeline by AFFiRiS AG, H1 2019
Pipeline by Arvinas Inc, H1 2019
Pipeline by Biogen Inc, H1 2019
Pipeline by Denali Therapeutics Inc, H1 2019
Pipeline by Fulcrum Therapeutics Inc, H1 2019
Pipeline by Genmab A/S, H1 2019
Pipeline by ICB International Inc, H1 2019
Pipeline by MedImmune LLC, H1 2019
Pipeline by Neuropore Therapies Inc, H1 2019
Pipeline by nLife Therapeutics SL, H1 2019
Pipeline by Priavoid GmbH, H1 2019
Pipeline by ProMIS Neurosciences Inc, H1 2019
Pipeline by Prothena Corp Plc, H1 2019
Pipeline by QR Pharma Inc, H1 2019
Pipeline by Seelos Therapeutics Inc, H1 2019
Pipeline by UCB SA, H1 2019
Pipeline by United Neuroscience Ltd, H1 2019
Pipeline by Voyager Therapeutics Inc, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019